Here are three stocks with buy rank and strong momentum characteristics for investors to consider today, January 31st:

ADMA Biologics, Inc. (ADMA Quick QuoteADMA - Free Report) : This biopharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 33.3% over the last 60 days.

ADMA Biologics Inc Price and Consensus

ADMA Biologics Inc price-consensus-chart | ADMA Biologics Inc Quote

ADMA’s shares gained 52% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score  of A.

ADMA Biologics Inc Price

ADMA Biologics Inc price | ADMA Biologics Inc Quote

Ekso Bionics Holdings, Inc. : This exoskeleton products company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing 25.6% over the last 60 days.

Ekso Bionics Holdings, Inc. Price and Consensus

Ekso Bionics Holdings, Inc. price-consensus-chart | Ekso Bionics Holdings, Inc. Quote

Ekso Bionics’ shares gained 56.9% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of A.

Ekso Bionics Holdings, Inc. Price

Ekso Bionics Holdings, Inc. price | Ekso Bionics Holdings, Inc. Quote

InhibikaseTherapeutics, Inc. (IKT Quick QuoteIKT - Free Report) : This clinical-stage pharmaceutical company has a Zacks Rank #1 and witnessed the Zacks Consensus Estimate for its current year earnings increasing nearly 16% over the last 60 days.

Inhibikase Therapeutics, Inc. Price and Consensus

Inhibikase Therapeutics, Inc. price-consensus-chart | Inhibikase Therapeutics, Inc. Quote

Inhibikase’s shares gained 270.6% over the last three months compared with the S&P 500’s advance of 16.1%. The company possesses a Momentum Score of B.

Inhibikase Therapeutics, Inc. Price

Inhibikase Therapeutics, Inc. price | Inhibikase Therapeutics, Inc. Quote

See the full list of top ranked stocks here

Learn more about the Momentum score and how it is calculated here.